Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis

Journal of Pediatrics

Volumn 175, Issue , 2016, Pages 150-158.e1

  Sontag, Marci K ^a   Lee, Rachel ^b,c   Wright, Daniel ^c   Freedenberg, Debra ^b   Sagel, Scott D ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^c Air Pollution Control Division   (United States)

^d University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

accuracy; carriers; cystic fibrosis related metabolic syndrome; neonatal screening

Indexed keywords

TRYPSINOGEN; BIOLOGICAL MARKER; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC MARKER;

ARTICLE; CLINICAL EVALUATION; COLORADO; CONTROLLED STUDY; CYSTIC FIBROSIS; DRIED BLOOD SPOT TESTING; FOLLOW UP; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MUTATION; NEWBORN; NEWBORN SCREENING; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SWEAT TEST; TEXAS; WYOMING; ALGORITHM; BLOOD; ENZYMOLOGY; FEMALE; GENETIC MARKER; GENETIC SCREENING; GENETICS; IMMUNOLOGICAL PROCEDURES; MALE; PROCEDURES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ALGORITHMS; BIOMARKERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRIED BLOOD SPOT TESTING; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC TESTING; HUMANS; IMMUNOLOGIC TESTS; INFANT, NEWBORN; MALE; MUTATION; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN; UNITED STATES;

EID: 84964680919     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.03.046     Document Type: Article

References (33)

1. NewSTEPs: Newborn Screening Technical assistance and Evaluation Program [homepage on the internet], 2015, Association of Public Health Laboratories, Silver Spring, MD.
2. Southern, K.W., Munck, A., Pollitt, R., Travert, G., Zanolla, L., Dankert-Roelse, J., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6 (2007), 57–65.
3. Massie, R.J., Curnow, L., Glazner, J., Armstrong, D.S., Francis, I., Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust 196 (2012), 67–70.
4. Wagener, J.S., Zemanick, E.T., Sontag, M.K., Newborn screening for cystic fibrosis. Curr Opin Pediatr 24 (2012), 329–335.
5. Crossley, J.R., Smith, P.A., Edgar, B.W., Gluckman, P.D., Elliott, R.B., Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots. Clin Chim Acta 113 (1981), 111–121.
6. Sontag, M.K., Corey, M., Hokanson, J.E., Marshall, J.A., Sommer, S.S., Zerbe, G.O., et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr 149 (2006), 650–657.
7. Hammond, K.B., Abman, S.H., Sokol, R.J., Accurso, F.J., Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 325 (1991), 769–774.
8. Gregg, R.G., Wilfond, B.S., Farrell, P.M., Laxova, A., Hassemer, D., Mischler, E.H., Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 52 (1993), 616–626.
9. Farrell, P.M., Aronson, R.A., Hoffman, G., Laessig, R.H., Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing. Wis Med J 93 (1994), 415–421.
10. Wilcken, B., Wiley, V., Sherry, G., Bayliss, U., Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 127 (1995), 965–970.
11. Comeau, A.M., Parad, R.B., Dorkin, H.L., Dovey, M., Gerstle, R., Haver, K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004), 1573–1581.
12. Baker, M.W., Groose, M., Hoffman, G., Rock, M., Levy, H., Farrell, P.M., Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros 10 (2011), 278–281.
13. Borowitz, D., Parad, R.B., Sharp, J.K., Sabadosa, K.A., Robinson, K.A., Rock, M.J., et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155 (2009), S106–S116.
14. Munck, A., Mayell, S.J., Winters, V., Shawcross, A., Derichs, N., Parad, R., et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 14 (2015), 706–713.
15. Sontag, M.K., Wright, D., Beebe, J., Accurso, F.J., Sagel, S.D., A new cystic fibrosis newborn screening algorithm: IRT/IRT1/DNA. J Pediatr 155 (2009), 618–622.
16. Kloosterboer, M., Hoffman, G., Rock, M., Gershan, W., Laxova, A., Li, Z., et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 123 (2009), e338–e346.
17. Castellani, C., Southern, K.W., Brownlee, K., Dankert Roelse, J., Duff, A., Farrell, M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 8 (2009), 153–173.
18. Kharrazi, M., Yang, J., Bishop, T., Lessing, S., Young, S., Graham, S., et al. Newborn screening for cystic fibrosis in California. Pediatrics 136 (2015), 1062–1072.
19. Smyth, A.R., Bell, S.C., Bojcin, S., Bryon, M., Duff, A., Flume, P., et al. European Cystic Fibrosis Society standards of care: best Practice guidelines. J Cyst Fibros 13:Suppl 1 (2014), S23–S42.
20. Rock, M.J., Hoffman, G., Laessig, R.H., Kopish, G.J., Litsheim, T.J., Farrell, P.M., Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr 147 (2005), S73–S77.
21. Sontag, M.K., Hammond, K.B., Zielenski, J., Wagener, J.S., Accurso, F.J., Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 147 (2005), S83–S88.
22. Tluczek, A., Orland, K.M., Cavanagh, L., Psychosocial consequences of false-positive newborn screens for cystic fibrosis. Qual Health Res 21 (2011), 174–186.
23. Tluczek, A., Koscik, R.L., Modaff, P., Pfeil, D., Rock, M.J., Farrell, P.M., et al. Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test. J Genet Couns 15 (2006), 277–291.
24. Prach, L., Koepke, R., Kharrazi, M., Keiles, S., Salinas, D.B., Reyes, M.C., et al. Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. J Mol Diagn 15 (2013), 710–722.
25. Petros, M., Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening?. Genet Med 14 (2012), 129–134.
26. Wilson, J.M.G., Jungner, G., Principles and practice of screening for disease. 1968, World Health Organization, Geneva, Switzerland.
27. Ren, C.L., Fink, A.K., Petren, K., Borowitz, D.S., McColley, S.A., Sanders, D.B., et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 135 (2015), e1386–e1392.
28. Ooi, C.Y., Castellani, C., Keenan, K., Avolio, J., Volpi, S., Boland, M., et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135 (2015), e1377–e1385.
29. Accurso, F.J., Sontag, M.K., Wagener, J.S., Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 147 (2005), S37–S41.
30. Kay, D.M., Langfelder-Schwind, E., DeCelie-Germana, J., Sharp, J.K., Maloney, B., Tavakoli, N.P., et al. Utility of a very high IRT/no mutation referral category in cystic fibrosis newborn screening. Pediatr Pulmonol 50 (2015), 771–780.
31. Gabler, E., Delays at hospitals across the country undermine newborn screening programs, putting babies at risk of disability and death. Milwaukee Journal Sentinal, 2013, Journal Sentinal, Inc, Milwaukee, WI.
32. Johnson, M., Testing delay puts newborn's life at risk. Milwaukee Journal Sentinal, 2013, Journal Sentinal, Inc, Milwaukee, WI.
33. Fauber, J., More than half of state labs do not process newborn samples on weekends, creating critical delays in the process. Milwaukee Journal Sentinal, 2013, Journal Sentinal, Inc, Milwaukee, WI.